219 related articles for article (PubMed ID: 20511978)
41. Pericardial effusions with tamponade and visceral constriction in patients with rheumatoid arthritis on tumour necrosis factor (TNF)-inhibitor therapy.
Soh MC; Hart HH; Corkill M
Int J Rheum Dis; 2009 Apr; 12(1):74-7. PubMed ID: 20374322
[TBL] [Abstract][Full Text] [Related]
42. [Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab].
D'Alessandro G; Bianco MR; Politis S; Ferrandina C; Rossi G; Altomare E
Reumatismo; 2006; 58(1):59-61. PubMed ID: 16639489
[TBL] [Abstract][Full Text] [Related]
43. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583
[TBL] [Abstract][Full Text] [Related]
44. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
45. [Antineutrophil cytoplasmic antibody associated vasculitis in a patient treated with adalimumab for a rheumatoid arthritis].
Fournier A; Nony A; Rifard K
Nephrol Ther; 2009 Dec; 5(7):652-7. PubMed ID: 19482531
[TBL] [Abstract][Full Text] [Related]
46. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
Ledingham J; Deighton C;
Rheumatology (Oxford); 2005 Feb; 44(2):157-63. PubMed ID: 15637039
[No Abstract] [Full Text] [Related]
47. Appearance of rheumatoid nodules following anti-tumor necrosis factor alpha treatment with adalimumab for rheumatoid arthritis.
Scrivo R; Spadaro A; Iagnocco A; Valesini G
Clin Exp Rheumatol; 2007; 25(1):117. PubMed ID: 17418005
[No Abstract] [Full Text] [Related]
48. Adalimumab for rheumatoid arthritis?
Ebell M; Kripke C
Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
[No Abstract] [Full Text] [Related]
49. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.
Boulton JG; Bourne JT
Rheumatology (Oxford); 2007 Jan; 46(1):178-9. PubMed ID: 16998233
[No Abstract] [Full Text] [Related]
50. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
51. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
[TBL] [Abstract][Full Text] [Related]
53. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
Strangfeld A; Hierse F; Kekow J; von Hinueber U; Tony HP; Dockhorn R; Listing J; Zink A
Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
[TBL] [Abstract][Full Text] [Related]
54. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Hochman D; Wolff B
JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
[No Abstract] [Full Text] [Related]
55. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Callegari PE; Schaible TF; Boscia JA
JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
[No Abstract] [Full Text] [Related]
56. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
Costenbader KH; Glass R; Cui J; Shadick N
JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
[No Abstract] [Full Text] [Related]
57. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J; Strangfeld A; Kekow J; Schneider M; Kapelle A; Wassenberg S; Zink A
Arthritis Rheum; 2008 Mar; 58(3):667-77. PubMed ID: 18311816
[TBL] [Abstract][Full Text] [Related]
58. [Rheumatoid arthritis: current status of therapy].
El Bahri DM; Meddeb N; Sellami S
Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
[TBL] [Abstract][Full Text] [Related]
59. Infliximab-associated pneumonitis in rheumatoid arthritis.
Hennum J; Nace J; Shammash E; Gertner E
J Rheumatol; 2006 Sep; 33(9):1917-8. PubMed ID: 16960963
[No Abstract] [Full Text] [Related]
60. A case of tuberculous peritonitis in the United States in a patient with rheumatoid arthritis treated with adalimumab.
Szeto T; Peterson J; Silva F
J Clin Rheumatol; 2010 Apr; 16(3):135-7. PubMed ID: 20375825
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]